Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2311752120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Zhongfeng Ye und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Tufts University, Medford, MA 02155. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Massachusetts Consortium on Pathogen Readiness, World reference center for emerging viruses and arboviruses.
Abstract (Originalsprache)
The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA, using the ancestral SARS-CoV-2 spike sequence, optimized 5′ and 3′ untranslated regions (UTRs), and LNP combinations. Our data showed that these nanocomplexes effectively activate CD4 + and CD8 + T cell responses and humoral immune response and provide complete protection against WA1/2020, Omicron BA.1 and BQ.1 infection in hamsters. Critically, in Omicron BQ.1 challenge hamster models, TU88mCSA and ALCmCSA not only induced robust control of virus load in the lungs but also enhanced protective efficacy in the upper respiratory airways. Antigen-specific immune analysis in mice revealed that the observed cross-protection is associated with superior UTRs [Carboxylesterase 1d (Ces1d)/adaptor protein-3β (AP3B1)] and LNP formulations that elicit robust lung tissue-resident memory T cells. Strong protective effects of TU88mCSA or ALCmCSA against both WA1/2020 and VOCs suggest that this mRNA-LNP combination can be a broadly protective vaccine platform in which mRNA cargo uses the ancestral antigen sequence regardless of the antigenic drift. This approach could be rapidly adapted for clinical use and timely deployment of vaccines against emerging and reemerging VOCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155.
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
- National Emerging Infectious Diseases Laboratories and Department of Virology, Immunology, and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02215.
- World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555.
- Department of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210.
- Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.
ORCID-Profile: Zhongfeng Ye, Srinivasa Reddy Bonam, Lindsay G A McKay, Jessica A Plante, Yamin Li, Joseph Harmon, Donghui Song, Zhibo Zhang, Kenneth S Plante, Anthony Griffiths, Jianzhu Chen
Förderung
- NIAID NIH HHS
- Massachusetts Consortium on Pathogen Readiness
- World reference center for emerging viruses and arboviruses
Zitieren
APA
Ye, Z., Bonam, S. R., McKay, L. G. A., Plante, J. A., Walker, J., Zhao, Y., Huang, C., Chen, J., Xu, C., Li, Y., Liu, L., Harmon, J., Gao, S., Song, D., Zhang, Z., Plante, K. S., Griffiths, A., Chen, J., Hu, H., & Xu, Q. (2023). Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2311752120
Vancouver
Ye Z, Bonam SR, McKay LGA, Plante JA, Walker J, Zhao Y, et al. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2311752120
BibTeX
@article{Ye2023,
author = {Ye, Zhongfeng and Bonam, Srinivasa Reddy and McKay, Lindsay G A and Plante, Jessica A and Walker, Jordyn and Zhao, Yu and Huang, Changfeng and Chen, Jinjin and Xu, Chutian and Li, Yamin and Liu, Lihan and Harmon, Joseph and Gao, Shuliang and Song, Donghui and Zhang, Zhibo and Plante, Kenneth S and Griffiths, Anthony and Chen, Jianzhu and Hu, Haitao and Xu, Qiaobing},
title = {Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2311752120}
}
EUVIMED